|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical application of a new device for minimally invasive circumcision显示文摘瞄准:与 phimosis 或过量包皮在不同年龄的男病人的治疗学习一台可处理的割礼设备的临床的效果。方法:在 5 和 95 年的年龄之间的 1200 个病人在在 2005 年 10 月和 2007 年 9 月之间的 2 年的时期用这个过程经历了割礼。这些盒子, 904 有过量包皮, 296 是 phimosis 的盒子。结果:在 96.33% 盒子中,切口愈合了,离开没有使好化妆结果留下疤痕并且生产的内部包皮的最小的数量。没有到系带的设备脱臼或损坏的事件。平均起作用的时间为 phimosis 是为过量包皮,和 3.5 min 的 2.5 min。在穿设备的 7 天期间,对中等浮肿温和与 phimosis 与过量包皮并且在那些的 2.58 % 发生在盒子的 10.08 % 。在系带的浮肿在 1.67% 病人被看见,并且仅仅, 0.67% 有切口的感染。86.25% 病人的一个总数由于阴茎勃起报导了疼痛。在设备的移动以后, 0.58% 案例有在切口附近的最小的流血,并且 2.42% 弯屈裂开。结论:新设备能与 phimosis 和过量包皮被用于病人的一个压到优势的多数。这种技术相对简单表现,并且经历了这个手术的病人有很少的复杂并发症。抗菌素没比用常规方法被割除的那些被要求,病人们报导了更少的疼痛。有这台设备的割礼要求最小的组织操作,并且比用常规技术的割礼更快、安全。 | Yi-Feng Peng Yue Cheng Guo-Yao Wang Suo-Qun Wang Chao Jia Ben-Hai Yang Ru Zhu Shu-Chuan Jian Qing-Wen Li Da-Wei Geng | 2008 | Asian Journal of Andrology2008，10，3： | 105 |
| 2 | No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo- controlled multicenter clinical trial (ENLEAT Trial)显示文摘在紧急情况以后的背景没有回流为尖锐的圣片断举起的经皮的冠的干预(一种总线标准) 心肌的梗塞(STEMI ) 与严重预后有关。这研究的目的是评估 Tongxinluo 的功效,繁体中文药,在在为 219 个病人全部的 STEMI.Methods A 的紧急情况一种总线标准以后的没有回流和梗塞区域上(女性 31 ,14%)从九个临床的中心为 STEMI 经历紧急情况一种总线标准连续地在这被注册使随机化,双窗帘,控制安慰剂, multicenter 对2009年5月的从2007年1月的临床的试用。所有病人随机被划分成 Tongxinluo 在装载的组(n=108 ) 和控制组(n=111 ) ,给定的 Tongxinluo 或安慰剂在紧急情况一种总线标准前分别地为 2.08 g 开 asprin 300 mg 和 clopidogrel 300 mg 一起,然后为在一种总线标准以后的六个月三倍每日的 1.04 g。圣片断举起被心电图在住院记录并且 1, 2, 6, 12,在冠的汽球膨胀到以后的 24 个小时评估心肌的没有流动;在有静态的单个光子的排放的 STEMI 计算了断层摄影术( SPECT )决定在那里的梗塞 area.Results 不是在性别的统计意义以后, 17 个片断的心肌的灌注分数在白天 7 和白天 180 上被评估,年龄经过历史,胸疼痛, onset-to-reperfusion 时间, Killip 分类,就在一种总线标准前后的 TIMI 流动等级,在药治疗的任何一个在follow 在上面期间例如 statin ,-blocker,血管收缩素变换酶禁止者( ACEI )或血管收缩素 rece 在与在 6 个小时的控制组相比的 Tongxinluo 组有重要的圣片断恢复((-0.22????????????????????????????? 慰桴灯票楳汯杯捩污吗?? | ZHANG Hai-tao JIA Zhen-hua ZHANG Jian YE Zan-kai YANG Wei-xian TIAN Yue-qin JIA Xuan LI Wei WU Yi-ling YANG Yue-jin | 2010 | Chinese Medical Journal2010，，20： | 69 |
| 3 | GPS-constrained inversion of present-day slip rates along major faults of the Sichuan-Yunnan region, China显示文摘A linked-fault-element model is employed to invert for contemporary slip rates along major active faults in the Sichuan-Yunnan region (96°-108°E, 21°-35°N) using the least squares method. The model is based on known fault geometry, and constrained by a GPS-derived horizontal velocity field. Our results support a model attributing the eastward extrusion of the Tibetan Plateau driven mainly by the north-northeastward indentation of the Indian plate into Tibet and the gravitational collapse of the plateau. Resisted by a relatively stable south China block, materials of the Sichuan-Yunnan region rotate clockwise around the eastern Himalayan tectonic syntaxis. During the process the Garzê-Yushu, Xianshuihe, Anninghe, Zemuhe, Daliangshan, and Xiaojiang faults, the southwest extension of the Xiaojiang fault, and the Daluo-Jinghong and Mae Chan faults constitute the northeast and east boundaries of the eastward extrusion, with their left slip rates being 0.3-14.7, 8.9-17.1, 5.1 ± 2.5, 2.8 ± 2.3, 7.1 ± 2.1, 9.4 ± 1.2, 10.1 ± 2.0, 7.3 ± 2.6, and 4.9 ± 3.0 mm/a respectively. The southwestern boundary consists of a widely distributed dextral transpressional zone other than a single fault. Right slip rates of 4.2 ± 1.3, 4.3 ± 1.1, and 8.5 ± 1.7 mm/a are detected across the Nanhua-Chuxiong-Jianshui, Wuliangshan, and Longling-Lancang faults. Crustal deformation across the Longmenshan fault is weak, with short-ening rates of 1.4 ± 1.0 and 1.6 ± 1.3 mm/a across the Baoxing-Beichuan and Beichuan-Qingchuan segments. Northwest of the Longmenshan fault lies an active deformation zone (the Longriba fault) with 5.1±1.2 mm/a right slip across. Relatively large slip rates are detected across a few faults within the Sichuan-Yunnan block: 4.4±1.3 mm/a left slip and 2.7±1.1 mm/a shortening across the Litang fault, and 2.7±2.3 mm/a right-lateral shearing and 6.7±2.3 mm/a shortening across the Yunongxi fault and its surrounding regions. In conclusion, we find that the Sichuan-Yunnan region is divided into more than a dozen active micro-blocks by a large number of faults with relatively slow slip rates. The eastward extrusion of the Tibetan Plateau is absorbed and adjusted in the region mainly by these faults, other than a small number of large strike-slip faults with fast slip rates. | WANG YanZhao WANG EnNing SHEN ZhengKang WANG Min GAN WeiJun QIAO XueJun MENG GuoJie LI TieMing TAO Wei YANG YongLin CHENG Jia LI Peng | 2008 | Science China Earth Sciences2008，51，9： | 65 |
| 4 | Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial显示文摘BACKGROUND: Disease recurrence is a main challenge in treatment of hepatocellular carcinoma (HCC). There is no generally accepted method for preventing recurrence of HCC after resection. OBJECTIVE: To compare the efficacy of a traditional herbal medicine (THM) regimen and transarterial chemoembolization (TACE) in preventing recurrence in post-resection patients with small HCC. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a multicenter, open-label, randomized, controlled study, which was undertaken in five centers of China. A total of 379 patients who met the eligibility criteria and underwent randomization were enrolled in this trial. One hundred and eighty-eight patients were assigned to the THM group and received Cinobufacini injection and Jiedu Granule, and the other 191 patients were assigned to the TACE group and received one single course of TACE. MAIN OUTCOME MEASURES: Primary outcome measures were the annual recurrence rate and the time to recurrence. Incidence of adverse events was regarded as the secondary outcome measure. RESULTS: Among the 364 patients who were included in the intention-to-treat analysis, 67 patients of the THM group and 87 of the TACE group had recurrence, with a hazard ratio of 0.695 (P = 0.048). Median recurrence-free survival of the patients in the THM and TACE groups was 46.89 and 34.49 months, respectively. Recurrence rates at 1, 2 and 3 years were 17.7%, 33.0% and 43.5% for the THM group, and 28.8%, 42.5% and 54.0% for the TACE group, respectively (P = 0.026). Multivariate analysis indicated that the THM regimen had a big advantage for prolonging the recurrence-free survival. Adverse events were mild and abnormality of laboratory indices of the two groups were similar. CONCLUSION: In comparison with TACE therapy, the THM regimen was associated with diminished risk of recurrence of small-sized HCC after resection, with comparable adverse events. TRIAL REGISTRTION IDENTIFIER: This trial was registered in the Chinese Clinical Trial Registry with the identifier ChiCTR-TRC-07000033. | Xiao-feng Zhai Zhe Chen Bai Li Feng Shen Jia Fan Wei-ping Zhou Yun-ke Yang Jing Xu Xiao Qin Le-qun Li Chang-quan Ling | 2013 | Journal of Integrative Medicine2013，11，2： | 49 |
| 5 | Ganoderic acid hinders renal fibrosis via suppressing the TGF- β/Smad and MAPK signaling pathways显示文摘Renal fibrosis is considered as the pathway of almost all kinds of chronic kidney diseases(CKD)to the end stage of renal diseases(ESRD).Ganoderic acid(GA)is a group of lanostane triterpenes isolated from Ganoderma lucidum,which has shown a variety of pharmacological activities.In this study we investigated whether GA exerted antirenal fibrosis effect in a unilateral ureteral obstruction(UUO)mouse model.After UUO surgery,the mice were treated with GA(3.125,12.5,and 50 mg·kg^−1·d^−1,ip)for 7 or 14 days.Then the mice were sacrificed for collecting blood and kidneys.We showed that GA treatment dose-dependently attenuated UUO-induced tubular injury and renal fibrosis;GA(50 mg·kg^−1·d^−1)significantly ameliorated renal disfunction during fibrosis progression.We further revealed that GA treatment inhibited the extracellular matrix(ECM)deposition in the kidney by suppressing the expression of fibronectin,mainly through hindering the over activation of TGF-β/Smad signaling.On the other hand,GA treatment significantly decreased the expression of mesenchymal cell markers alpha-smooth muscle actin(α-SMA)and vimentin,and upregulated E-cadherin expression in the kidney,suggesting the suppression of tubular epithelial-mesenchymal transition(EMT)partially via inhibiting both TGF-β/Smad and MAPK(ERK,JNK,p38)signaling pathways.The inhibitory effects of GA on TGF-β/Smad and MAPK signaling pathways were confirmed in TGF-β1-stimulated HK-2 cell model.GA-A,a GA monomer,was identified as a potent inhibitor on renal fibrosis in vitro.These data demonstrate that GA or GA-A might be developed as a potential therapeutic agent in the treatment of renal fibrosis. | Xiao-qiang Geng Ang Ma Jin-zhao He Liang Wang Ying-li Jia Guang-ying Shao Min Li Hong Zhou Shu-qian Lin Jian-hua Ran Bao-xue Yang | 2020 | Acta Pharmacologica Sinica2020，41，5： | 43 |
| 6 | De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis显示文摘AIM:To compare efficacy of combined lamivudine(LAM)and adefovir dipivoxil(ADV)therapy with that of entecavir(ETV)monotherapy for hepatitis B virus(HBV)-related decompensated liver cirrhosis.METHODS:A total of 120 na ve patients with HBVrelated decompensated cirrhosis participated in this study.Sixty patients were treated with combined LAM and ADV therapy(LAM+ADV group),while the other60 were treated with ETV monotherapy(ETV group)for two years.Tests for liver and kidney function,alpha-fetoprotein,HBV serum markers,HBV DNA load,prothrombin time(PT),and ultrasonography or computed tomography scan of the liver were performed every1 to 3 mo.Repeated measure ANOVA and theχ2test were performed to compare the efficacy,side effects,and the cumulative survival rates at 48 and 96 wk.RESULTS:Forty-five patients in each group were observed for 96 wk.No significant differences in HBV DNA negative rates and alanine aminotransferase(ALT)normalization rates at weeks 48(χ2=2.12 and 2.88)and96(χ2=3.21 and 3.24)between the two groups were observed.Hepatitis B e antigen seroconversion rate in the LAM+ADV group at week 96 was significantly higher in the ETV group(43.5%vs 36.4%,χ2=4.09,P<0.05).Viral breakthrough occurred in 2 cases(4.4%)by week 48 and in 3 cases(6.7%)by week 96 in the LAM+ADV group,and no viral mutation was detected.In the ETV group,viral breakthrough occurred in 1 case(2.2%)at the end of week 96.An increase in albumin(F=18.9 and 17.3),decrease in total bilirubin and in ALT(F=16.5,17.1 and 23.7,24.8),reduced PT(F=22.7 and 24.5),and improved Child-Turcotte-Pugh and the model for end-stage liver disease scores(F=18.5,17.8,and 24.2,23.8)were observed in both groups.The cumulative rates of mortality and liver transplantation were 16.7%(10/60)and 18.3%(11/60)in the LAM+ADV and ETV groups,respectively.CONCLUSION:Both LAM+ADV combination therapy and ETV monotherapy can effectively inhibit HBV replication,improve liver function,and decrease mortality. | Jiang-Shan Lian Lin-Yan Zeng Jian-Yang Chen Hong-Yu Jia Yi-Min Zhang Dai-Rong Xiang Liang Yu Jian-Hua Hu Ying-Feng Lu Ling Zheng Lan-Juan Li Yi-Da Yang | 2013 | World Journal of Gastroenterology2013，19，37： | 36 |
| 7 | Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients显示文摘Human infection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)causes coronavirus disease 2019(COVID-19)and there is no cure currently.The 3CL protease(3CLpro)is a highly conserved protease which is indispensable for CoVs replication,and is a promising target for development of broad-spectrum antiviral drugs.In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian preparation,a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China.We showed that either the oral liquid of Shuanghuanglian,the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-23CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.Baicalin and baicalein,two ingredients of Shuanghuanglian,were characterized as the first noncovalent,nonpeptidomimetic inhibitors of SARS-CoV-23CLpro and exhibited potent antiviral activities in a cell-based system.Remarkably,the binding mode of baicalein with SARS-CoV-23CLpro determined by X-ray protein crystallography was distinctly different from those of known 3CLpro inhibitors.Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues,the crucial S1/S2 subsites and the oxyanion loop,acting as a“shield”in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site.Overall,this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target,and gains evidence supporting the in vivo studies of Shuanghuanglian oral liquid as well as two natural products for COVID-19 treatment. | Hai-xia Su Sheng Yao Wen-feng Zhao Min-jun Li Jia Liu Wei-juan Shang Hang Xie Chang-qiang Ke Hang-chen Hu Mei-na Gao Kun-qian Yu Hong Liu Jing-shan Shen Wei Tang Lei-ke Zhang Geng-fu Xiao Li Ni Dao-wen Wang Jian-ping Zuo Hua-liang Jiang Fang Bai Yan Wu Yang Ye Ye-chun Xu | 2020 | Acta Pharmacologica Sinica2020，41，9： | 32 |
| 8 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 9 | 26mA cm^(-2) J_(sc) from organic solar cells with a low-bandgap nonfullerene acceptor显示文摘Nonfullerene-based organic solar cells(NFOSCs)have received great interest recently due to their higher performance and greater potential compared with fullerene-based solar cells[1].Power conversion efficiencies(PCEs)over 13% have been realized in single-junction NFOSCs[2].Compared with traditional fullerene acceptors,the greatest advantage of nonfullerene acceptors is their stronger light-harvesting capability in the visible and | Zuo Xiao Xue Jia Dan Li Shizhe Wang Xinjian Geng Feng Liu Junwu Chen Shangfeng Yang Thomas P.Russell Liming Ding | 2017 | Science Bulletin2017，62，22： | 28 |
| 10 | Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL:An observational study显示文摘BACKGROUND Nucleos(t)ide analog(NA)has shown limited effectiveness against hepatitis B surface antigen(HBsAg)clearance in chronic hepatitis B(CHB)patients.AIM To evaluate the efficacy and safety of add-on peginterferonα-2a(peg-IFNα-2a)to an ongoing NA regimen in CHB patients.METHODS In this observational study,195 CHB patients with HBsAg≤1500 IU/m L,hepatitis B e antigen(HBeAg)-negative(including HBeAg-negative patients or HBeAg-positive patients who achieved HBeAg-negative after antiviral treatment with NA)and hepatitis B virus-deoxyribonucleic acid<1.0×10^2 IU/mL after over 1 year of NA therapy were enrolled between November 2015 and December2018 at the Second Affiliated Hospital of Xi'an Jiaotong University,China.Patients were given the choice between receiving either peg-IFNα-2a add-on therapy to an ongoing NA regimen(add-on group,n=91)or continuous NA monotherapy(monotherapy group,n=104)after being informed of the benefits and risks of the peg-IFNα-2a therapy.Total therapy duration of peg-IFNα-2a was 48 wk.All patients were followed-up to week 72(24 wk after discontinuation of peg-IFNα-2a).The primary endpoint was the proportion of patients with HBsAg clearance at week 72.RESULTS Demographic and baseline characteristics were comparable between the two groups.Intention-to-treatment analysis showed that the HBsAg clearance rate in the add-on group and monotherapy group was 37.4%(34/91)and 1.9%(2/104)at week 72,respectively.The HBsAg seroconversion rate in the add-on group was 29.7%(27/91)at week 72,and no patient in the monotherapy group achieved HBsAg seroconversion at week 72.The HBsAg clearance and seroconversion rates in the add-on group were significantly higher than in the monotherapy group at week 72(P<0.001).Younger patients,lower baseline HBsAg concentration,lower HBsAg concentrations at weeks 12 and 24,greater HBsAg decline from baseline to weeks 12 and 24 and the alanine aminotransferase≥2×upper limit of normal during the first 12 wk of therapy were strong predictors of HBsAg clearance in patients with peg-IFNα-2a add-on treatment.Regarding the safety of the treatment,4.4%(4/91)of patients in the add-on group discontinued peg-IFNα-2a due to adverse events.No severe adverse events were noted.CONCLUSION Peg-IFNα-2a as an add-on therapy augments HBsAg clearance in HBeAg-negative CHB patients with HBsAg≤1500 IU/m L after over 1 year of NA therapy. | Feng-Ping Wu Ying Yang Mei Li Yi-Xin Liu Ya-Ping Li Wen-Jun Wang Juan-Juan Shi Xin Zhang Xiao-Li Jia Shuang-Suo Dang | 2020 | World Journal of Gastroenterology2020，26，13： | 27 |
| 11 | Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor显示文摘 | Lijie Wang Wei Xue Lei Yan Xiaosa Li Jia Wei Miaomiao Chen Jing Wu Bei Yang Li Yang Jia Chen | 2017 | Cell Research2017，27，10： | 26 |
| 12 | Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species显示文摘 | Chen-chun ZHONG Feng CHEN Jun-ling YANG Wei-wei JIA Li LI Chen CHENG Fei-fei DU Su-ping ZHANG Chengying XIE Na-ting ZHANG Olajide E OLALEYE Feng-qing WANG Fang XU Li-guang LOU Dong-ying CHEN Wei NIU Chuan LI | 2018 | Acta Pharmacologica Sinica2018，39，6： | 24 |
| 13 | Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185^(c-erbB-2)显示文摘The c-erbB-2 proto-oncogene encodes a 185kDa protein p185, which belongs to epidermal growth factorreceptor family. Amplification of this gene has been shown to correlate with poor clinical prognosis forcertain cancer patients. The monoclonal antibody A21 which directed against p185 specifically inhibitsproliferation of tumor cells overexpressing p185, hence allows it to be a candidate for targeted therapy. Inorder to overcome several drawbacks of murine MAb, we cloned its VH and VL genes and constructed thesingle-chain Fv (scFv) through a peptide linker. The recombinant scFvA21 was expressed in Escherichiacoli and purified by the affinity column. Subsequently it was characterized by ELISA, Western blot, cellimmunohistochemistry and FACS. All these assays showed the binding activity to extracellular domain(ECD) of p185. Based on those properties of scFvA21, we further constructed the scFv-Fc fusion moleculewith a homodimer form and the recombinant product was expressed in mammalian cells. In a series ofsubsequent analysis this fusion protein showed identical antigen binding site and activity with the parentantibody. These anti-p185 engineered antibodies have promised to be further modified as a tumor targetingdrugs, with a view of application in the diagnosis and treatment of human breast cancer. | LIAN SHENG CHENG, AI PING LIU, JIA HONG YANG, YAN QIU DONG, LIANG WEI LI, JING WANG, CHAO CHEN WANG, JING LIUSchool of Life Science, University of Science and Technology of China, Hefei 230027, China | 2003 | Cell Research2003，13，1： | 24 |
| 14 | 圆柱形锂离子动力电池放电过程电化学与传热特性研究显示文摘 | XU Meng ZHANG Zhuqian JIA Li YANG Lixin | 2013 | 中国电机工程学报2013，33，32： | 23 |
| 15 | Chemical Constituents from Leaves of Camellia nitidissima and Their Potential Cytotoxicity on SGC7901 Cells显示文摘Objective To isolate and identify the bioactive phytochemicals from the leaves of Camellia nitidissima. Methods The chemical constituents were isolated and purified by repeated silica gel, Sephadex LH-20, MCI gel columns, recrystallization, and semi-preparative HPLC techniques. The chemicl structures of these compounds were identified on the basis of spectral data including NMR and MS. Then quorum sensing inhibition(QSI) activities of these compounds were tested using Chromobacterium violaceum CV026 as the bioindicator strain. The antitumor activities of these compounds were measured using SGC7901 as cell proliferation and cytotoxicity. Resultsα-Spinasteryl-β-D-glucopyranoside(1), stigmasta-7,22-diene-3-O-[α-L-arabinopyranosyl(1→2)]-β-D-galactopyranoside(2), kaempferol 3-O-[2-O-(trans-p-coumaroyl)-3-O-α-D-glucopyranosyl]-α-D-glucopyranoside(3), aromadendrin(4), catechin(5), phlorizin 4′-O-β-D-glucopyranoside(6),(3R,6R,7E)-3-hydroxy-4,7-megastigmadien-9-one(7), dodecanoic acid(8), 3β-acetoxy-20-lupanol(9), and 3β,6α,13β-trihydroxyolean- 7-one(10) were successively isolated from the leaves of C. nitidissima. Unfortunately, these compounds had no QSI activity. Based on Cell Counting Kit-8(CCK-8) assay, compound 10 showed the best anti-tumor activity of all compounds(IC50 = 91.7 μg/m L). Conclusion Apart from compounds 4 and 5, other eight compounds are reported in this plant for the first time. All compounds show no QSI activity, compound 10 shows potential cytotoxic activity on SGC7901 cells in vitro. | Jing Qi Ruo-fu Shi Jian-ming Yu Yi Li Sheng-tao Yuan Ji-zhu Yang Jiang-miao Hu Ai-qun Jia | 2016 | Chinese Herbal Medicines2016，8，1： | 23 |
| 16 | Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota显示文摘BACKGROUND We previously showed,using the Traditional Chinese Medicine System Pharmacology Database,that Gegen Qinlian decoction(GQD)had a direct antitumor effect,and was combined with programmed cell death protein(PD)-1 inhibitors to treat microsatellite stable(MSS)tumor-bearing mice.However,the effect of GQD on patients with colorectal cancer(CRC)is not clear.AIM To determine the therapeutic mechanism of GQD in improving immune function,reducing inflammation and protecting intestinal barrier function.METHODS Seventy patients with CRC were included in this study:37 in the control group and 33 in the treatment group.The proportions of CD4+T,CD8+T,natural killer(NK),NKT and T regulatory cells were measured by flow cytometry.Levels of the cytokines tumor necrosis factor(TNF)-α,interferon(IFN)-γ,interleukin(IL)-2,IL-6,IL-10 and serotonin(5-hydroxytryptamine;5-HT)in serum were assessed by enzyme-linked immunosorbent assay(ELISA).The expression of zonula occludens(ZO)-1,occludin,nuclear factor(NF)-κB and TNF-αin tumor and normal tissues was measured by immunohistochemistry.The composition of gut microbiota from patients in the treatment group was assessed using 16S rDNA analysis.RESULTS There were no adverse events in the treatment group.The proportion of CD4+T cells and NKT cells in the post-treatment group was significantly higher than that in the pre-treatment and control groups(P<0.05).The level of TNF-αin the posttreatment group was significantly lower than that in the pre-treatment and control groups(P<0.05).The concentration of 5-HT in the post-treatment group was significantly lower than that in the pre-treatment group(P<0.05).The expression of ZO-1 and occludin in tumor tissues in the treatment group was significantly higher than that in the control group(P<0.05).The expression of ZO-1 in normal tissues of the treatment group was significantly higher than that in the control group(P=0.010).Compared with the control group,expression of NF-κB and TNF-αin tumor tissues of the treatment group was significantly decreased(P<0.05).Compared with the pre-treatment group,GQD decreased the relative abundance of Megamonas and Veillonella.In addition,GQD increased the relative abundance of Bacteroides,Akkermansia and Prevotella.CONCLUSION GQD enhances immunity and protects intestinal barrier function in patients with CRC by regulating the composition of gut microbiota. | Yang Li Zhong-Xin Li Chen-Yang Xie Jing Fan Ji Lv Xin-Jian Xu Jian Lv Wen-Tao Kuai Yi-Tao Jia | 2020 | World Journal of Gastroenterology2020，26，48： | 23 |
| 17 | Evaluation of the 7^(th) edition of the TNM classification in patients with resected esophageal squamous cell carcinoma显示文摘AIM:To evaluate the prognostic factors and tumor stages of the 7th edition TNM classification for esophageal cancer.METHODS:In total,1033 patients with esophageal squamous cell carcinoma(ESCC)who underwent surgical resection with or without(neo)adjuvant therapy between January 2003 and June 2012 at the Thoracic Surgery DepartmentⅡof the Beijing Cancer Hospital,Beijing,China were included in this study.The following eligibility criteria were applied:(1)squamous cell carcinoma of the esophagus or gastroesophageal junction identified by histopathological examination;(2)treatment with esophagectomy plus lymphadenectomy with curative intent;and(3)complete pathologic reports and follow-up data.Patients who underwent non-curative(R1)resection and patients who died in hospital were excluded.Patients who received(neo)adjuvant therapy were also included in thisanalysis.All patients were restaged using the 7th edition of the Union for International Cancer Control and the American Joint Committee on Cancer TNM staging systems.Univariate and multivariate analyses were performed to identify the prognostic factors for survival.Survival curves were plotted using the Kaplan-Meier method,and the log-rank test was used to evaluate differences between the subgroups.RESULTS:Of the 1033 patients,273 patients received(neo)adjuvant therapy,and 760 patients were treated with surgery alone.The median follow-up time was 51.6mo(range:5-112 mo)and the overall 5-year survival rate was 36.4%.Gender,'p T'and'p N'descriptors,(neo)adjuvant therapy,and the 7th edition TNM stage grouping were independent prognostic factors in the univariate and multivariate analyses.However,neither histologic grade nor cancer location were independent prognostic factors in the univariate and multivariate analyses.The 5-year stage-based survival rates were as follows:ⅠA,84.9%;ⅠB,70.9%;ⅡA,56.2%;ⅡB,43.3%;ⅢA,37.9%;ⅢB,23.3%;ⅢC,12.9%andⅣ,3.4%.There were significant differences between each adjacent staging classification.Moreover,there were significant differences between each adjacent p N and p M subgroup.According to the p T descriptor,there were significant differences between each adjacent subgroup except between p T3 and p T4(P=0.405).However,there was no significant difference between each adjacent histologic grade subgroup and between each adjacent cancer location subgroup.CONCLUSION:The 7th edition is considered to be valid for patients with resected ESCC.However,the histologic grade and cancer location were not prognostic factors for ESCC. | Jia Wang Nan Wu Qing-Feng Zheng Shi Yan Chao Lv Shao-Lei Li Yue Yang | 2014 | World Journal of Gastroenterology2014，20，48： | 23 |
| 18 | Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B显示文摘AIM: To evaluate urine β2-microglobulin(β2-M), retinol-binding protein(RBP) excretion, and renal impairment with adefovir dipivoxil(ADV) for chronic hepatitis B. METHODS: We enrolled 165 patients with chronic hepatitis B infection who were treated with ADV monotherapy(n = 90) or ADV plus lamivudine combination therapy(n = 75). An additional 165 chronic hepatitis B patients treated with entecavir were recruited as controls. We detected serum creatinine, urine β2-M, and RBP levels, and estimated the glomerular filtration rate(e GFR) at the initiation of antiviral therapy and every 6 mo for a period of five years. RESULTS: Urine β2-M abnormalities were observed in patients during the first(n = 3), second(n = 7), third(n = 11), fourth(n = 16), and fifth(n = 21) year of ADV treatment. Urinary RBP abnormalities were observed in patients during the first(n = 2), second(n = 8), third(n = 12), fourth(n = 15), and fifth(n = 22) year of ADV treatment. e GFR decreased 20%-30% from baseline in 20 patients, 30%-50% in 12 patients, and > 50% in 3 patients during the five years of treatment. Further analysis indicated that decreases in e GFR of ≥ 30% relative to the baseline level correlated significantly with urine RBP and β2-M abnormalities. In contrast, both serum creatinine and e GFR remained stable in patients treated with entecavir, and only one of these patients developed a urine β2-M abnormality, and two developed urine RBP abnormalities during the five years of treatment. CONCLUSION: Urine RBP and β2-M are biomarkers of renal injury during long-term ADV treatment for chronic hepatitis B, and indicate when treatment should be switched to entecavir. | Hong-Yu Jia Feng Ding Jian-Yang Chen Jiang-Shan Lian Yi-Min Zhang Lin-Yan Zeng Dai-Rong Xiang Liang Yu Jian-Hua Hu Guo-Dong Yu Huan Cai Ying-Feng Lu Lin Zheng Lan-Juan Li Yi-Da Yang | 2015 | World Journal of Gastroenterology2015，21，12： | 22 |
| 19 | Posterior scleral reinforcement for the treatment of pathological myopia显示文摘AIM: To investigate the effects of posterior scleral reinforcement(PSR) in the treatment of pathological myopia.·METHODS: The study included 52 eyes in 43 patients with pathological myopia who underwent PSR(PSR group), and 52 eyes in 36 age- and myopia-matched patients who did not undergo such treatment as control group. Axial length, refraction error, best corrected visual acuity(BCVA), and macular scans by optical coherence tomography(OCT) were recorded at baseline, 6mo, 1, 3and 5y after the surgery, and the complications were noted.·RESULTS: There were no statistical differences in axial length, refractive error, or BCVA between the PSR group and the control group at baseline. At the end of the follow-up, the mean axial length was 29.79 ±1.26 mm in the PSR group, which was significantly shorter than that in the control group(30.78±1.30 mm)(P <0.01), and the mean refractive error was-16.86 ±2.53 D in the PSR group, which was significantly lower than that in the control group(-19.18 ±2.12 D)(P <0.01). A statistically significant difference in BCVA was found between the PSR group(0.51 ±0.25 log MAR) and the control group(0.62±0.26 log MAR) at the postoperative 5-year follow-up(P <0.01). There were no serious complications during the 5-year follow-up period.·CONCLUSION: PSR can prevent axial elongation and myopia progression in eyes with pathological myopia. | Xiu-Juan Li Xiao-Peng Yang Qiu-Ming Li Yu-Ying Wang Yuan Wang Xiao-Bei Lyu Heng Jia | 2016 | International Journal of Ophthalmology(English edition)2016，9，4： | 21 |
| 20 | Neutrophil-to-lymphocyte ratio compared to N-terminal pro-brain natriuretic peptide as a prognostic marker of adverse events in elderly patients with chronic heart failure显示文摘BackgroundThe neutrophil-to-lymphocyte (N/L ) 比率与心失败在病人与差的预后被联系了,但是它一直不在有长期的心失败(CHF ) 的老病人与 N 终端支持大脑的 natriuretic 肽(NT-proBNP ) 相比。我们寻求了与 CHF 1355 个老病人使这 comparison.MethodsA 全部被分析。multivariate 逻辑回归模型被用来分析与 atrial 纤维性颤动(AF ) 联系的变量。考克斯回归分析被用来估计在 N/L 比率, NT-proBNP 水平,和随后的主要心血管的事件(MCE ).ResultsIn 之间的 multivariable 关系多重逻辑回归分析, N/L 比率与 CHF 在老病人为 AF 作为一个风险因素被表明[机会比率(或) :1.079, 95% 信心间隔(CI ) :1.027-1.134, P = 0.003 ] 。中部的后续时期是 18 个月。在用两个变量的 tertiles 的一个 multivariable 模型, N/L 比率的最高的 tertile 显著地与 MCE 被联系[危险比率(HR ) :1.407, 95% CI:1.098-1.802, P = 0.007 ] 与最低 tertile 相比。同样,最高的 NT-proBNP tertile 显著地也与 MCE 被联系(HR:1.461, 95% CI:1.104-1.934, P = 0.008 ).ConclusionsIn 有 CHF 的老病人, N/L 比率是为 AF 的重要风险因素之一,它是有到 NT-proBNP 的类似的独立预示的力量的一个便宜、容易地可得到的标记。当 N/L 比率被提高到最高的 tertile 时, MCE 的风险增加 1.407 褶层。 | Wei YAN Rui-Jun LI Qian JIA Yang MU Chun-Lei LIU Kun-Lun HE | 2017 | Journal of Geriatric Cardiology2017，14，2： | 20 |
您所在的机构暂未开通此部分的功能，请联系管理员